The first COPD patient has been dosed in a Phase 1b COPD trial testing Bambusa Therapeutics’ dual-target therapy BBT002.
Demonstrates how dual-purpose therapeutic targets may address both hepatocellular carcinoma progression and cellular ...
Demonstrates how dual-purpose therapeutic targets may address both hepatocellular carcinoma progression and cellular senescence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback